Low-molecular-weight Heparins in Therapy of Thromboembolic Diseases

Assesses the efficacy and safety of using this new class of antithrombotic agents in the prevention and treatment of venous thromboembolism - explaining the advantages of low-molecular-weight heparins, as compared with regular, unfractionated heparins.

---

Detailing the basic and clinical science of low-molecular-weight heparins, this reference assesses the efficacy and safety of using this new class of antithrombotic agents in the prevention and treatment of venous thromboembolism, explaining the advantages of low-molecular-weight heparins, as compared with regular, unfractionated heparins. Containing the contributions of over 25 specialists from Europe and North America, "Low-Molecular-Weight Heparins in prophylaxis and Therapy of Thromboembolic Diseases": investigates the pharmacology, mechanisms of action, and laboratory monitoring of low-molecular-weight heparins; offers a first appraisal of the use of low-molecular-weight heparins in the treatment of established venous thromboembolism; presents systematic overviews of the use of low-molecular-weight heparins in the prevention of venous thromboembolism following general, neuro-, and orthopedic surgery, and in immobilized medical patients, as well as in extracorporeal circuits; and delineates the interactions of low-molecular-weight heparin compounds with endothelial cells, blood platelets, the fibrinolytic system, and the proliferation of smooth muscle tissue.
This resource is intended for: cardiologists; specialists in vascular medicine; hematologists; vascular, cardiovascular, and orthopedic surgeons; anesthesiologists; clinical pharmacologists; pulmonologists; gynecologists; and upper-level undergraduate, graduate, and medical school students in these disciplines.